Antibody-drug conjugates combined with immunotherapy: a potential game changer in the treatment of upper tract urothelial carcinoma
10.3760/cma.j.cn112139-20240124-00049
- VernacularTitle:抗体偶联药物联合免疫治疗用于上尿路尿路上皮癌的现状与挑战
- Author:
Zhijie LU
1
;
Yuan LI
Author Information
1. 中南大学湘雅二医院泌尿外科，长沙 410012
- Keywords:
Urethral neoplasms;
Antibodies, neoplasm;
Upper tract urothelial carcinoma;
Antibody-drug conjugate;
Immunotherapy;
Chemotherapy;
Enfortumab;
Vedotinumab
- From:
Chinese Journal of Surgery
2024;62(8):737-743
- CountryChina
- Language:Chinese
-
Abstract:
Currently, treatment strategies for upper tract urothelial carcinoma (UTUC) are changing rapidly. However, there are many limitations in the implementation of new surgical methods and systemic treatment options, which cannot reverse the current status quo of UTUC treatment. In recent years, antibody-drug conjugates have shown great potential in the field of cancer treatment, which can activate the immune system and enhance the effect of immunotherapy while accurately killing targeted tumor cells. The results of multiple clinical trials, including the EV-302 study, have confirmed that combination therapy can improve the survival rate of patients with advanced urothelial cancer, and may replace chemotherapy as the first-line treatment for advanced urothelial cancer. However, there are still a series of challenges in the application of combination therapy in UTUC, such as low level of evidence, adverse reactions, and drug resistance. In the future, it is necessary to focus on clinical trials of UTUC combination therapy, further optimize antibody drug conjugates and immunotherapy drugs to adapt to the disease characteristics of UTUC, and further study the molecular biology characteristics of UTUC to meet this series of challenges.
